Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: How Should We Approach Milestones While Grieving? Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutations How Should We Approach Milestones While Grieving? Dec 17, 2018 09:00 am | Tré LaRosa When Serena Lawrence, the late BioNews senior columns editor, responded to my email about potentially writing for Cystic Fibrosis News Today and promptly offered me a columnist position, I was awestruck. This was the first concrete (read: monetary) endorsement of my writing. My hope with this column was to talk about polarizing topics in the CF […] The post How Should We Approach Milestones While Grieving? appeared first on Cystic Fibrosis News Today. Read More Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutations Dec 17, 2018 07:00 am | Jose Marques Lopes, PhD Health Canada has approved Orkambi (ivacaftor/lumacaftor) to treat preschoolers with cystic fibrosis (CF) who carry the F508del mutation in both gene copies of the CFTR gene. Orkambi, developed by Vertex Pharmaceuticals, in the first disease-modifying therapy in Canada for children ages 2 to 5 with CF. It previously was approved in the country for patients with two  F508del mutations starting […] The post Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutationsappeared first on Cystic Fibrosis News Today. Read More   Recent News Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections Specific Sweat Test Better Detects Kalydeco’s Effects on CFTR Function, Study Suggests Your CF Partner Can Help Make You Healthier Young CF Patients Deem Wrist-worn Devices Acceptable for Monitoring Physical Activity, Study Finds Higher Interleukin-7 Serum Levels Could be Biomarker for CF, Study Suggests